Alpha-Thalassemia: Luspatercept Treatment Study

We are investigating whether Luspatercept can improve anemia in adults and adolescents with Alpha-thalassemia. The study will also assess the safety of this treatment in younger participants.

Efficacy phase (II)Post-Trial Drug AccessPartially RemoteStandard MedicinesInjectionHematology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Reblozyl
Reblozyl is a medicine for adults that helps treat severe anemia caused by beta-thalassemia or certain bone marrow disorders.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Luspatercept
Luspatercept is a substance that helps increase red blood cell production to treat certain types of anemia and reduce the need for transfusions.
Sodium Chloride Solution 0.9%
Sodium chloride 0.9% is a sterile salt solution used to replace fluids and electrolytes, hydrate patients, and clean wounds or body cavities.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Hippokration Hospital
Thalassemia Unit
Athens, Greece
General Hospital Of Larissa Koutlibaneio And Triantafylleio
Department of Thalassemia
Lárisa, Greece
General University Hospital Of Patras
Bone Marrow Transplantation Unit
Pátra, Greece
Sponsor: Celgene Corp.
Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.